drugset / Trial / NCT00787072

AZD8075 Single Ascending Dose Study

NCT00787072 ↗

Phase 1 Terminated 72 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindBasic science

Summary

The aim of this study is to assess the safety, tolerability and pharmacokinetics of single ascending oral doses of AZD8075 in healthy male volunteers

Timeline

Start
2008-10
Primary completion
2009-01
Completion
2009-01

Outcome

Outcome not reported

Stopped: “After reports of turbidity in urine in 4 of 8 volunteers in the 4th cohort, the study was halted temporarily.”

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8075 Small molecule 7 mg Oral

Indications

No indication recorded.